COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 488

Article download: 179

Indian Journal of Clinical Anaesthesia

Intrathecal midazolam for prevention of nausea and vomiting during and after cesarean section under spinal anaesthesia

Full Text PDF Share on Facebook Share on Twitter

Author Details : Amol Singam, Arpita Jaiswal, Rashmi Deshpande Tapan Dhumey

Volume : 5, Issue : 2, Year : 2018

Article Page : 228-232

Suggest article by email


Introduction: Relevant incidences of nausea-vomiting during and immediately after cesarean section in spinal anesthesia are found to be high. Effectiveness of intrathecal midazolam (2 mg) as an adjuvant to bupivacaine on the incidence and severity of intraoperative and immediate postoperative nausea and vomiting was investigated in the present study.
Materials and Methods: A randomized, controlled, double-blind study was conducted in 120 healthy women (ASA Physical status I and II) scheduled for elective cesarean section under spinal anesthesia. Parturients were randomly divided into two equal groups of 60 each. Group M(study group) -Patients received 10 mg (2.0ml) of 0.5% hyperbaric bupivacaine combined with 2 mg (0.4 ml) midazolam intrathecally and Group C (control group)- 10 mg (2.0ml) of 0.5% hyperbaric bupivacaine combined with 0.4 ml normal saline intrathecally. Assessment of the patients were done for incidence of nausea-vomiting, hemodynamic effects and occurrence of adverse effects during cesarean section and during first 6 hours after the operation.
Results: Incidence of emetic symptoms in Group M were significantly lower than Group C (15% vs 63.34%, p< 0>). There were no clinically serious adverse events observed in any of the groups. All neonates had APGAR scores more than 8 at one and five minutes.
Conclusion: Intrathecal midazolam as an adjuvant to Bupivacaine is associated with lower incidence of nausea and vomiting with no neonatal adverse effects.

Keywords: Nausea, Vomiting, Intrathecal midazolam, Spinal anesthesia, Cesarean section.

Doi : 10.18231/2394-4994.2018.0042

How to cite : Singam A, Jaiswal A, Dhumey R D T, Intrathecal midazolam for prevention of nausea and vomiting during and after cesarean section under spinal anaesthesia. Indian J Clin Anaesth 2018;5(2):228-232

Copyright © 2018 by author(s) and Indian J Clin Anaesth. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (